D.E. Shaw & Co
CAPR icon

D.E. Shaw & Co’s Capricor Therapeutics CAPR Stock Holding History

D.E. Shaw & Co’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.58M Hold
315,000
– – 0.01% 1676
2025
Q4 		$9.09M Buy
315,000
+250,000
+385% +$3.26M 0.01% 1848
2025
Q3 		$469K Buy
+65,000
New +$479K ﹤0.01% 3894

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co's CAPR Position: Q4 2025 in Review

D.E. Shaw & Co sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 15,945 shares — an estimated $208K sold.

D.E. Shaw & Co first reported a position in CAPR in Q4 2024 and held it in 3 quarters. The position peaked at $742K in Q4 2024. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • D.E. Shaw & Co reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,945 Capricor Therapeutics shares in Q4 2025, an estimated $208K.
  • D.E. Shaw & Co first reported a position in Capricor Therapeutics in Q4 2024 and held it in 3 quarters.
  • D.E. Shaw & Co's Capricor Therapeutics position peaked at $742K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.